Skip to contentO
OptimizeRx Corp
O
OPRXOptimizeRx Corp Q1 2017 · 10-Q
Revenue$2.15M$2.15M+22.3% vs Q1 2016 Net Income-$882.68K-$882.68KN/M vs Q1 2016 EPS Diluted-$0.03-$0.03N/M vs Q1 2016 Gross Profit$770,340−11.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
OptimizeRx Corp · CIK 1448431 · Engraved from SEC EDGAR
Operating Cash Flow-$297,236N/M Free Cash Flowderived-$313,382N/M Margins · derivedGross margin35.8%−13.5 pt vs Q1 2016
Operating margin-41.4%−20.8 pt vs Q1 2016
Net margin-41.0%−21.0 pt vs Q1 2016
ended Mar 31, 2017 · filed May 3, 2017 · 33 d after period end